The technology will improve clinical outcomes by reducing preterm births, new born morbidity and lifelong disabilities.
TALLAHASSEE, Fla. (PRWEB) July 23, 2018
The Company’s Board of Directors has appointed Marc Lawrence as the CEO. According to Board Chairman and Partner at Newport Board Group, Don Rosenkoetter, “Marc is a proven senior executive with extensive experience in developing and accelerating profitable growth for Medical Device/Technology businesses. In addition to being intimate with the investor community, his global business development experience and acumen will deliver value to the customers we serve and our shareholders.” Marc’s background includes senior executive experiences at Johnson &Johnson, Philips Healthcare and HeartSine Technologies/Stryker.
Effective immediately, Melanie Simmons, PhD. President of KynderMed has assumed key strategic responsibilities as Chief Development Officer for the business. In her role, Melanie will be instrumental in product evolution and market development activities.
About KynderMed’s Approach
KynderMed is employing novel proprietary technology developed by Dr. James Olcese, Professor of Biomedical Sciences, Neuroscience and Molecular Biophysics at Florida State University’s College of Medicine.
The prospect of moving this technology to the women who so desperately need a safe and effective means to carry their babies to full term and avoid the tragedy that preterm birth creates a tremendous passion and energy among our team.
KynderMed is being advised by the Newport Board Group.
KynderMed, Inc. is a Tallahassee Florida based Innovative medical device company with proprietary technology regulating uterine contractions in pregnant women. The technology will improve clinical outcomes by reducing preterm births, new born morbidity and lifelong disabilities.
Melanie Simmons, PhD
President & CDO